On the basis of interim results from a clinical trial, Merck pulled Vioxx off the market. The results indicate that patients who have been taking the drug for 18 months have twice the risk of suffering a heart attack or stroke than those taking a placebo. Vioxx had worldwide sales of $2.5 billion last year. While Merck’s action was generally lauded, critics argue that earlier studies indicated this issue as well. The stock market reacted swiftly, reducing the price from $45 to $33. Now Merck and its investors must brace for the inevitable lawsuits from those who believe they were harmed by the drug. Beyond the legal liabilities, Merck also faces challenges from expiring patents on successful drugs and the risky business of developing and marketing new drugs.
“Merck Pulls Vioxx From Market After Link to Heart Problems,” by Barbara Martinez and others, Wall Street Journal, Thursday, October 1, 2004, page A1.
1. Why did Merck’s price fall so significantly?
2. As CEO of Merck, Raymond Gilmartin made the decision to stop sales of Vioxx. Should he have withheld this information since it would have a clear negative effect on share price and he has an obligation to maximize the value of these shares?
3.How can Merck rebuild its share value after the Vioxx recall?